2 results about "Triolein" patented technology

The invention discloses treprostinil multivesicular liposome for treating pulmonary arterial hypertension. The multivesicular liposome is prepared from an inner water phase, an oil phase and an outer water phase through a double emulsification method, the treprostinil is dissolved in the inner water phase; the oil phase comprises soybean lecithin, cholesterol, glyceryl trioleate and electronegative lipid; the inner water phase and the outer water phase are body fluid isotonic solutions. The treprostinil multivesicular liposome disclosed by the invention has good stability and high encapsulation efficiency, obviously reduces burst release effect, shows obvious slow release characteristic, is beneficial to prolonging in-vivo drug half-life period, and can realize 48-hour treatment, reduce administration frequency, simplify administration method and improve patient compliance through simple subcutaneous injection. After the treprostinil multivesicular liposome is injected once, the inflammatory reaction of the injection part can be eliminated within 7 days, and the treprostinil multivesicular liposome has good safety.

The present invention relates to a stratum corneum retention improver including an ester of a component A that is ditrimethylolpropane, and a component B that is one or more fatty acids selected from saturated fatty acids having 6 to 12 carbon atoms. The present invention further relates to a shine-inhibiting agent including an ester of component A and component B, wherein the ester has a hydroxyl value of 140 mgKOH / g or less, and which inhibits shine caused by one or more oily components selected from the group consisting of squalene, triolein, macadamia seed oil, trimethylolpropane triisostearate, pentaerythrityl tetraisostearate, hydrogenated polyisobutene, hydrogenated polydecene, coco-caprylate / caprate, octyldodecyl myristate, and polyglyceryl-2 diisostearate.